Develops prescription software treatments for psychiatric and neurological conditions. Its cleared product, Motivista, treats the negative symptoms of schizophrenia as an adjunct to antipsychotic therapy.
One email, every morning
THE MORNING BRIEF
New clearances, funding rounds and regulatory moves for device founders, and every new how-to guide and template as it lands. No noise, no login.
✓
You're in. The next morning brief lands in your inbox.
No Spam. Unsubscribe anytime.
By registering, you agree to receive communications from us. Your information may also be shared with sponsors and partners identified on this Site for relevant industry communications. You may unsubscribe at any time. See our Privacy Policy.